Skip to main content
Top
Published in: BMC Pediatrics 1/2020

Open Access 01-12-2020 | Fabry Disease | Case report

Cornea Verticillata in classical Fabry disease, first from Sri Lanka: a case report

Authors: Hasani Hewavitharana, Eresha Jasinge, Hiranya Abeysekera, Jithangi Wanigasinghe

Published in: BMC Pediatrics | Issue 1/2020

Login to get access

Abstract

Background

Fabry disease is a rare inborn error of metabolism with profound clinical consequences if untreated. It is caused by the deficiency of α galactosidase A enzyme and is the only lysosomal storage disorder with an X linked inheritance. Confirmation requires genetic analysis of Galactosidase Alpha (GLA) Gene, which is often a challenge in resource-poor settings. Despite these technological limitations, specific clinical features in this condition can establish the diagnosis.

Case presentation

We report on a 13-year old male who presented with an afebrile convulsion with a background history of chronic burning sensation of hands and feet and anhidrosis for 2 years duration with a similar history of episodic acroparesthesia in the other male sibling. The early clinical diagnosis was based on the history and detection of Cornea Verticillata on eye examination. Biochemical confirmation was established with detection of low α galactosidase A enzyme levels and a missense mutation of the Galactosidase Alpha (GLA) Gene (c.136C > T) established the genetic confirmation.

Conclusion

This is the first case of Fabry disease reported in Sri Lanka. Awareness of specific clinical features aided clinical diagnosis long before access to genetic confirmation was available.
Literature
1.
2.
go back to reference Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRef Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRef
3.
go back to reference Vedder AC, Strijland A, Vd Bergh Weerman MA, Florquin S, Aerts JMFG, Hollak CEM. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis2006;29 (1):106–111. Vedder AC, Strijland A, Vd Bergh Weerman MA, Florquin S, Aerts JMFG, Hollak CEM. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis2006;29 (1):106–111.
4.
go back to reference Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat. 2001;18(5):459.CrossRef Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat. 2001;18(5):459.CrossRef
5.
go back to reference Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631–41.CrossRef Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631–41.CrossRef
6.
go back to reference Mehta A, Ricci R, Widmer U, Dehout F, Garcia De Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Investig. 2004;34(3):236–42.CrossRef Mehta A, Ricci R, Widmer U, Dehout F, Garcia De Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Investig. 2004;34(3):236–42.CrossRef
7.
go back to reference Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–38.CrossRef Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–38.CrossRef
8.
go back to reference Elleder M, Bradová V, Smíd F, BudĚšínský M, Harzer K, Kustermann-Kuhn B, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease - report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449–55.CrossRef Elleder M, Bradová V, Smíd F, BudĚšínský M, Harzer K, Kustermann-Kuhn B, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease - report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449–55.CrossRef
9.
go back to reference Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry outcome survey. Br J Ophthalmol. 2007;91(2):210–4.CrossRef Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry outcome survey. Br J Ophthalmol. 2007;91(2):210–4.CrossRef
10.
go back to reference Hauser AC, Lorenz M, Voigtländer T, Födinger M, Sunder-Plassmann G. Results of an ophthalmologic screening programme for identification of cases with Anderson-fabry disease. Ophthalmologica. 2004;218(3):207–9.CrossRef Hauser AC, Lorenz M, Voigtländer T, Födinger M, Sunder-Plassmann G. Results of an ophthalmologic screening programme for identification of cases with Anderson-fabry disease. Ophthalmologica. 2004;218(3):207–9.CrossRef
11.
go back to reference Moiseev SV, Ismailova DS, Moiseev AS, Bulanov NM, Karovaikina EA, Nosova NR, et al. Cornea verticillata in Fabry disease. Ter Arkh. 2018;90(12):17–22.PubMed Moiseev SV, Ismailova DS, Moiseev AS, Bulanov NM, Karovaikina EA, Nosova NR, et al. Cornea verticillata in Fabry disease. Ter Arkh. 2018;90(12):17–22.PubMed
12.
go back to reference Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol. 2016;16:202.CrossRef Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol. 2016;16:202.CrossRef
13.
go back to reference Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: recommendations of the national society of genetic counselors. J Genet Couns. 2013;22(5):555–64.CrossRef Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: recommendations of the national society of genetic counselors. J Genet Couns. 2013;22(5):555–64.CrossRef
14.
go back to reference Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, Dambrosia JM, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002;26(5):622–9.CrossRef Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, Dambrosia JM, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002;26(5):622–9.CrossRef
15.
go back to reference Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1–2):57–61.CrossRef Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1–2):57–61.CrossRef
16.
Metadata
Title
Cornea Verticillata in classical Fabry disease, first from Sri Lanka: a case report
Authors
Hasani Hewavitharana
Eresha Jasinge
Hiranya Abeysekera
Jithangi Wanigasinghe
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Fabry Disease
Published in
BMC Pediatrics / Issue 1/2020
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-020-02237-z

Other articles of this Issue 1/2020

BMC Pediatrics 1/2020 Go to the issue